Verano Holdings (VRNO) Cash from Financing Activities (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Cash from Financing Activities of -$12.4 million for Q1 2026, down 1994.42% year-over-year from $653393.9 in Q1 2025, and down 230.61% quarter-over-quarter from -$3.7 million in Q4 2025.
Verano Holdings (VRNO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Cash from Financing Activities for 6 consecutive years, with -$12.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 1994.42% year-over-year to -$12.4 million; the TTM figure through Mar 2026 stood at -$37.1 million (up 42.2% YoY), while the FY2025 annual figure was -$25.3 million, up 61.59% from the prior year.
- Cash from Financing Activities fell to -$12.4 million in Q1 2026 per VRNO's latest filing, from -$3.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $92.8 million in Q1 2022 and bottomed at -$53.2 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $586705.9 across 5 years, with a median of -$2.3 million in 2024.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities surged 975.57% — and 2026, when it slumped 1994.42%.
- Verano Holdings' Cash from Financing Activities stood at $2.1 million in 2022, then soared by 975.57% to $22.3 million in 2023, then sank by 137.15% to -$8.3 million in 2024, then soared by 54.84% to -$3.7 million in 2025, then sank by 230.61% to -$12.4 million in 2026.
- Business Quant data shows VRNO's Cash from Financing Activities at -$12.4 million in Q1 2026, -$3.7 million in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Verano Holdings | 449.04 Mn | 363.85 Mn | 99.70 Mn | -7.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.61 Mn |
| Jun 30, 2026 | -7.61 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Mar 31, 2025 | -591,000.00 |
| Mar 31, 2025 | -591,000.00 |
| Dec 31, 2024 | -8.29 Mn |
| Dec 31, 2024 | -8.29 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | -53.15 Mn |
| Jun 30, 2024 | -53.15 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Mar 31, 2024 | -2.32 Mn |